Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC
- Friday, April 16, 2021, 7:17
- PR Newswire
- Add a comment
SEOUL, South Korea and JINAN, China, April 16, 2021 /PRNewswire/ — Peptron, Inc. (“Peptron”, KOSDAQ: 087010), a South Korea-based biotech company, and Qilu Pharmaceutical (“Qilu”), a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing…
About the Author
admin has written 20533 stories on this site.